MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$36,650,000
EPS
-$2.34
Unit: Dollar
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
0
-
-650,000*
0
Research and development
23,899,000
25,217,000
36,825,000*
28,535,000
General and administrative
8,250,000
5,710,000
5,748,500*
5,277,000
Total operating expenses
32,149,000
30,927,000
42,573,500*
33,812,000
Loss from operations
-32,149,000
-30,927,000
-43,223,500*
-33,812,000
Gain related to transaction with acquirer
-
-
0*
0
Interest expense
5,693,000
3,509,000
2,713,000*
3,181,000
Interest income
1,263,000
1,007,000
1,688,500*
1,783,000
Other expense, net
-68,000
-12,000
57,000*
-46,000
Total other expense
-4,498,000
-2,514,000
-967,500*
-1,444,000
Loss before income tax expense
-36,647,000
-33,441,000
-44,191,000*
-35,256,000
Provision for income taxes
3,000
0
-1,000*
0
Net loss
-36,650,000
-33,441,000
-44,190,000
-35,256,000
Basic EPS
-2.34
-2.15
-2.848
-2.28
Diluted EPS
-2.34
-2.15
-2.848
-2.28
Basic Average Shares
15,669,000
15,585,000
15,515,000
15,478,000
Diluted Average Shares
15,669,000
15,585,000
15,515,000
15,478,000
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss-$36,650,000 (-27.91%↓ Y/Y)Loss before incometax expense-$36,647,000 (-27.90%↓ Y/Y)Provision for income taxes$3,000 (50.00%↑ Y/Y)Loss from operations-$32,149,000 (-17.38%↓ Y/Y)Total other expense-$4,498,000 (-256.14%↓ Y/Y)Interest income$1,263,000 (-40.54%↓ Y/Y)Total operatingexpenses$32,149,000 (12.06%↑ Y/Y)Interest expense$5,693,000 (81.25%↑ Y/Y)Other expense, net-$68,000 (72.36%↑ Y/Y)Research and development$23,899,000 (7.33%↑ Y/Y)General andadministrative$8,250,000 (28.46%↑ Y/Y)

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. (INBX)